Bremelanotide clinical trials
Also written PT-141.
How each study uses bremelanotide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 21 Jun 2019 · VYLEESI (AUTOINJECTOR) · NDA 210557 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2006 (1)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 1
Palatin Technologies, Inc (6) · Cosette Pharmaceuticals, Inc. (1) · Kwang Dong Pharmaceutical co., ltd. (1) · Imperial College Healthcare NHS Trust (1)
Studies
Open first, then newest update. How each study uses bremelanotide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast MilkCompletedPhase 4Cosette Pharmaceuticals, Inc.NCT06867835Written as Vyleesi (Bremelanotide Injection)
- A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of ObesityActive, not recruitingPhase 2Palatin Technologies, IncNCT06565611Written as bremelanotide
- A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)CompletedPhase 3Kwang Dong Pharmaceutical co., ltd.NCT04943068Written as Bremelanotide
- A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseaseCompletedPhase 2Palatin Technologies, IncNCT05709444Written as Bremelanotide
- Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire DisorderCompletedPhase 4Imperial College Healthcare NHS TrustNCT04179734Written as Bremelanotide
- 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderCompletedPhase 3Palatin Technologies, IncNCT02333071Written as Bremelanotide
- 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderCompletedPhase 3Palatin Technologies, IncNCT02338960Written as Bremelanotide
- Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire DisorderCompletedPhase 2Palatin Technologies, IncNCT01382719Written as bremelanotide
- Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)CompletedPhase 2Palatin Technologies, IncNCT00425256Written as Bremelanotide
Given beside what is tested · 1 — bremelanotide is usual care or a partner of the new treatment
Codes
What other systems call bremelanotide · ClinicalTrials.gg INT004554
- MeSH (NLM) C476721bremelanotideConfirmed NLM, Wikidata
- UNII (FDA) 6Y24O4F92SBREMELANOTIDEConfirmed FDA, NLM, Wikidata
- RxNorm 2176312Confirmed FDA, Wikidata
- Wikidata Q415353bremelanotideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77009BremelanotideOne source FDA
- DrugBank DB11653One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C476721 | bremelanotide | Confirmed NLM, Wikidata |
| UNII (FDA) | 6Y24O4F92S | BREMELANOTIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2176312 | — | Confirmed FDA, Wikidata |
| Wikidata | Q415353 | bremelanotide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77009 | Bremelanotide | One source FDA |
| DrugBank | DB11653 | — | One source Wikidata |
Also registered as bremelanotide acetate (UNII PV2WI7495P · RxNorm 2176311).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.